Author(s) |
(Date) |
Paper Title |
Citation |
Model Type |
Applications |
Full Text |
| Cohen SM, et al. Mouse over for full list |
(2001) | Alternative models for carcinogenicity testing. | Toxicol. Sci. 64(1):14-9 | |||
| Toyosawa K, et al. Mouse over for full list |
(2001) | Di(2-ethylhexyl)phthalate induces hepatocellular adenoma in transgenic mice carrying a human prototype c-Ha-ras gene in a 26-week carcinogenicity study. | Toxicol Pathol 29(4):458-66 | |||
| Koujitani T, et al. Mouse over for full list |
(2001) | Lack of modifying effects of eugenol on development of lung proliferative lesions induced by urethane in transgenic mice carrying the human prototype c-Ha-ras gene. | J Toxicol Sci 26(3):129-39 | |||
| Birumachi J, et al. Mouse over for full list |
(2001) | Diesel exhaust-induced airway hyperresponsiveness in c-Ha-ras transgenic mice. | Toxicology 163(2-3):145-52 | |||
| Torii M, et al. Mouse over for full list |
(2001) | Twenty-six-week carcinogenicity study of sulfamethoxazole in CB6F1-Tg-rasH2 mice. | J Toxicol Sci 26(2):61-73 | |||
| Mori I, et al. Mouse over for full list |
(2001) | Aberrant expression of cyclin D1 in pulmonary proliferative lesions induced by high doses of urethane in transgenic mice carrying the human prototype c-H-ras gene. | J. Vet. Med. Sci. 63(3):261-8 | |||
| Kobayashi K, et al. Mouse over for full list |
(2000) | Glomerulonephritis with fibrillary deposition in a transgenic mouse carrying the human prototype c-Ha-ras gene (rasH2 mouse). | Toxicol Pathol 28(2):359-62 | |||
| Mori I, et al. Mouse over for full list |
(2000) | Carcinogen dose-dependent variation in the transgene mutation spectrum in urethane-induced lung tumors in transgenic mice carrying the human prototype c-Ha-ras gene. | Cancer Lett. 153(1-2):199-209 | |||
| Mitsumori K, et al. Mouse over for full list |
(1998) | Pulmonary fibrosis caused by N-methyl-N-nitrosourethane inhibits lung tumorigenesis by urethane in transgenic mice carrying the human prototype c-Ha-ras gene. | Cancer Lett. 129(2):181-90 | |||
| Hayashi S, et al. Mouse over for full list |
(1998) | Point mutations of the c-H-ras gene in spontaneous liver tumors of transgenic mice carrying the human c-H-ras gene. | Toxicol Pathol 26(4):556-61 | |||
| Yamamoto S, et al. Mouse over for full list |
(1998) | Validation of transgenic mice carrying the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. | Environ. Health Perspect. 106 Suppl 1:57-69 | |||
| Tsunematsu S, et al. Mouse over for full list |
(1997) | Role of H-ras gene in chronic liver damage in mice. By using transgenic mice carrying a human C-H-ras proto-oncogene without mutations. | Biochem. Mol. Biol. Int. 42(2):371-9 | |||
| Tsunematsu S, et al. Mouse over for full list |
(1997) | Susceptibility of experimental autoimmune hepatitis in transgenic mice overexpressing the c-H-ras gene. | J. Gastroenterol. Hepatol. 12(4):319-24 | |||
| Tsunematsu S, et al. Mouse over for full list |
(1994) | Hepatic tumors induced by carbon tetrachloride in transgenic mice carrying a human c-H-ras proto-oncogene without mutations. | Int. J. Cancer 59(4):554-9 | |||
| Doi ST, et al. Mouse over for full list |
(1994) | Site-specific mutation of the human c-Ha-ras transgene induced by dimethylbenzanthracene causes tissue-specific tumors in mice. | Jpn. J. Cancer Res. 85(8):801-7 | |||
| Ando K, et al. Mouse over for full list |
(1992) | Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. | Cancer Res. 52(4):978-82 | |||
| Muto S, et al. Mouse over for full list |
(2006) | Rapid induction of skin tumors in human but not mouse c-Ha-ras proto-oncogene transgenic mice by chemical carcinogenesis. | Cancer Sci. 97(9):842-7 | |||
| Urano K, et al. Mouse over for full list |
(2007) | Examination of percutaneous application in a 26-week carcinogenicity test in CB6F1-TG rasH2 mice. | J Toxicol Sci 32(4):367-75 | |||
| Kawabe M, et al. Mouse over for full list |
(2013) | Tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in an ultra-short-term skin carcinogenesis bioassay using rasH2 mice. | Vet. Pathol. 50(5):903-8 | |||
| Krishna G, et al. Mouse over for full list |
(2015) | Reversibility of dopamine receptor antagonist-induced hyperprolactinemia and associated histological changes in Tg RasH2 wild-type mice. | Reprod. Toxicol. 58:73-8 | |||
| Fielden MR, et al. Mouse over for full list |
(2016) | Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism. | Int. J. Toxicol. 35(3):294-308 | |||
| Sano T, et al. Mouse over for full list |
(2016) | Accumulation of Mott cells in the spleen in a CB6F1-Tg rasH2 mouse. | J Toxicol Pathol 29(4):265-268 | |||
| Suguro M, et al. Mouse over for full list |
(2017) | Lung Tumor Induction by 26-week Dermal Application of 1,2-Dichloroethane in CB6F1-Tg rasH2 Mice. | Toxicol Pathol 45(3):427-434 | |||
| Sano T, et al. Mouse over for full list |
(2017) | Immunohistochemical characterization of urethane-induced lung tumors in CB6F1-Tg rasH2 mice. | J Toxicol Pathol 30(2):177-181 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2017) | Tg.rasH2 Mice and not CByB6F1 Mice Should Be Used for 28-Day Dose Range Finding Studies Prior to 26-Week Tg.rasH2 Carcinogenicity Studies. | Int. J. Toxicol. 36(4):287-292 | |||
| Kuroda H, et al. Mouse over for full list |
(2018) | Progression process and safety assessment adaptation of endometrial lesions in ENU-induced 2-stage uterine carcinogenicity in a Tg-rasH2 mouse model. | J Toxicol Pathol 31(1):35-41 | |||
| Boyle MH, et al. Mouse over for full list |
(2018) | High Background Incidence of Spontaneous Subcapsular Adrenal Gland Hyperplasia of Tg.rasH2 Mice Used in 26-week Carcinogenicity Studies. | Toxicol Pathol 46(4):444-448 | |||
| Teo S, et al. Mouse over for full list |
(2018) | The Antitussive Benzonatate Is Not Tumorigenic in Rodent Carcinogenicity Studies. | Toxicol Pathol 46(6):683-692 | |||
| Kim TW, et al. Mouse over for full list |
(2019) | Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice. | Toxicol Pathol 47(1):82-92 | |||
| Fujiwara K, et al. Mouse over for full list |
(2019) | Inhibitory Effects of Glucosylceramide on Tumorigenesis Induced by a Carcinogen in Mice. | Laryngoscope | |||
| Chen R, et al. Mouse over for full list |
(2020) | Assessment of Pig-a, Micronucleus, and Comet Assay Endpoints in Tg.RasH2 Mice Carcinogenicity Study of Aristolochic Acid I. | Environ. Mol. Mutagen. 61(2):266-275 | |||
| Nishimura I, et al. Mouse over for full list |
(2019) | Carcinogenicity of intermediate frequency magnetic field in Tg.rasH2 mice. | Bioelectromagnetics 40(3):160-169 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2019) | A Comparison of Spontaneous Tumors in Tg.rasH2 Mice in 26-week Carcinogenicity Studies Conducted at a Single Test Facility during 2004 to 2012 and 2013 to 2018. | Toxicol Pathol 47(1):18-25 | |||
| Suarez-Torres JD, et al. Mouse over for full list |
(2020) | Drug excipients, food additives, and cosmetic ingredients probably not carcinogenic to humans reveal a functional specificity for the 2-year rodent bioassay. | J Appl Toxicol | |||
| Suarez-Torres JD, et al. Mouse over for full list |
(2020) | The 2-year rodent bioassay in drug and chemical carcinogenesis testing: Sensitivity, according to the framework of carcinogenic action. | Toxicol. Mech. Methods 30(6):462-475 | |||
| Koujitani T, et al. Mouse over for full list |
(2000) | Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene (rasH2 mice) to phenolphthalein in a 6-month carcinogenicity study. | Cancer Lett. 152(2):211-6 | |||
| Urano K, et al. Mouse over for full list |
(2012) | Establishing a laboratory animal model from a transgenic animal: RasH2 mice as a model for carcinogenicity studies in regulatory science. | Vet. Pathol. 49(1):16-23 | |||
| Ozaki M, et al. Mouse over for full list |
(2005) | Susceptibilities of p53 knockout and rasH2 transgenic mice to urethane-induced lung carcinogenesis are inherited from their original strains. | Toxicol Pathol 33(2):267-71 | |||
| Lee BS, et al. Mouse over for full list |
(2015) | A 28-day oral gavage toxicity study of 3-monochloropropane-1,2-diol (3-MCPD) in CB6F1-non-Tg rasH2 mice. | Food Chem. Toxicol. 86:95-103 | |||
| Shah SA, et al. Mouse over for full list |
(2012) | Reduction in the number of animals and the evaluation period for the positive control group in Tg.rasH2 short-term carcinogenicity studies. | Int. J. Toxicol. 31(5):423-9 | |||
| Umemura T, et al. Mouse over for full list |
(2002) | The mouse rasH2/BHT model as an in vivo rapid assay for lung carcinogens. | Jpn. J. Cancer Res. 93(8):861-6 | |||
| Watanabe T, et al. Mouse over for full list |
(2002) | Rapid induction of uterine endometrial proliferative lesions in transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) given a single intraperitoneal injection of N-ethyl-N-nitrosourea. | Cancer Lett. 188(1-2):39-46 | |||
| Palazzi X, et al. Mouse over for full list |
(2009) | Use of rasH2 transgenic mice for carcinogenesis testing of medical implants. | Exp. Toxicol. Pathol. 61(5):433-41 | |||
| Kawai M, et al. Mouse over for full list |
(2008) | Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice. | Toxicol Pathol 36(7):950-7 | |||
| Okamura M, et al. Mouse over for full list |
(2004) | Analysis of gene expression profiles of forestomach tumors in rasH2 mice initiated with N-ethyl-N-nitrosourea. | Arch. Toxicol. 78(12):688-96 | |||
| Storer RD, et al. Mouse over for full list |
(2003) | Transgenic tumor models for carcinogen identification: the heterozygous Trp53-deficient and RasH2 mouse lines. | Mutat. Res. 540(2):165-76 | |||
| Katsutani N, et al. Mouse over for full list |
(2000) | Hepatic drug metabolizing enzymes induced by clofibrate in rasH2 mice. | Toxicol. Lett. 115(3):223-9 | |||
| Sobajima A, et al. Mouse over for full list |
(2019) | Organ accumulation and carcinogenicity of highly dispersed multi-walled carbon nanotubes administered intravenously in transgenic rasH2 mice. | Int J Nanomedicine 14:6465-6480 | |||
| Okamura M, et al. Mouse over for full list |
(2004) | Carcinogenic susceptibility to N-bis(2-hydroxypropyl)nitrosamine (DHPN) in rasH2 mice. | Toxicol Pathol 32(4):474-81 | |||
| Cho WS, et al. Mouse over for full list |
(2011) | 26-Week carcinogenicity study of di-isodecyl phthalate by dietary administration to CB6F1-rasH2 transgenic mice. | Arch. Toxicol. 85(1):59-66 | |||
| Machida K, et al. Mouse over for full list |
(2008) | Carcinogenic comparative study on rasH2 mice produced by two breeding facilities. | J Toxicol Sci 33(4):493-501 | |||
| Okamura M, et al. Mouse over for full list |
(2007) | The possible mechanism of enhanced carcinogenesis induced by genotoxic carcinogens in rasH2 mice. | Cancer Lett. 245(1-2):321-30 | |||
| Umemura T, et al. Mouse over for full list |
(1999) | Susceptibility to urethane carcinogenesis of transgenic mice carrying a human prototype c-Ha-ras gene (rasH2 mice) and its modification by butylhydroxytoluene. | Cancer Lett. 145(1-2):101-6 | |||
| Jin M, et al. Mouse over for full list |
(2007) | Carcinogenic susceptibility of rasH2 mice to troglitazone. | Arch. Toxicol. 81(12):883-94 | |||
| Park HJ, et al. Mouse over for full list |
(2011) | Identification of biomarkers of chemically induced hepatocarcinogenesis in rasH2 mice by toxicogenomic analysis. | Arch. Toxicol. 85(12):1627-40 | |||
| Umemura T, et al. Mouse over for full list |
(2006) | Nine-week detection of six genotoxic lung carcinogens using the rasH2/BHT mouse model. | Cancer Lett. 231(2):314-8 | |||
| Narushima S, et al. Mouse over for full list |
(2010) | Inhibitory effect of yogurt on aberrant crypt foci formation in the rat colon and colorectal tumorigenesis in RasH2 mice. | Exp. Anim. 59(4):487-94 | |||
| Nesfield SR, et al. Mouse over for full list |
(2005) | Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse. | Int. J. Toxicol. 24(5):301-11 | |||
| Nambiar PR, et al. Mouse over for full list |
(2012) | Spontaneous tumor incidence in rasH2 mice: review of internal data and published literature. | Toxicol Pathol 40(4):614-23 | |||
| Tsuji S, et al. Mouse over for full list |
(2015) | Gene expression analysis in the lung of the rasH2 transgenic mouse at week 4 prior to induction of malignant tumor formation by urethane and N-methylolacrylamide. | J Toxicol Sci 40(6):685-700 | |||
| Tomisawa M, et al. Mouse over for full list |
(2003) | Mutation analysis of vinyl carbamate or urethane induced lung tumors in rasH2 transgenic mice. | Toxicol. Lett. 142(1-2):111-7 | |||
| Takanashi S, et al. Mouse over for full list |
(2012) | Carcinogenicity evaluation for the application of carbon nanotubes as biomaterials in rasH2 mice. | Sci Rep 2:498 | |||
| Curtin GM, et al. Mouse over for full list |
(2004) | Lung tumorigenicity in A/J and rasH2 transgenic mice following mainstream tobacco smoke inhalation. | Toxicol. Sci. 81(1):26-34 | |||
| Umemura T, et al. Mouse over for full list |
(2001) | Butylhydroxytoluene (BHT) increases susceptibility of transgenic rasH2 mice to lung carcinogenesis. | J. Cancer Res. Clin. Oncol. 127(10):583-90 | |||
| Imai T, et al. Mouse over for full list |
(2002) | Inhibitory effects of cinnamaldehyde on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung carcinogenesis in rasH2 mice. | Cancer Lett. 175(1):9-16 | |||
| Takaoka M, et al. Mouse over for full list |
(2003) | Interlaboratory comparison of short-term carcinogenicity studies using CB6F1-rasH2 transgenic mice. | Toxicol Pathol 31(2):191-9 | |||
| Tamaoki N Mouse over for full list |
(2001) | The rasH2 transgenic mouse: nature of the model and mechanistic studies on tumorigenesis. | Toxicol Pathol 29 Suppl:81-9 | |||
| Nambiar PR, et al. Mouse over for full list |
(2013) | The rasH2 mouse model for assessing carcinogenic potential of pharmaceuticals. | Toxicol Pathol 41(8):1058-67 | |||
| Bogdanffy MS, et al. Mouse over for full list |
(2020) | Tg.rasH2 Mouse Model for Assessing Carcinogenic Potential of Pharmaceuticals: Industry Survey of Current Practices. | Int. J. Toxicol. :1091581820919896 | ADMET | ||
| Kawabe M, et al. Mouse over for full list |
(2019) | Establishment and Validation of an Ultra-Short-Term Skin Carcinogenicity Bioassay Using Tg-rasH2 Mice. | Vet. Pathol. :300985819854440 | |||
| Saitoh A, et al. Mouse over for full list |
(1990) | Most tumors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. | Oncogene 5(8):1195-200 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2013) | Historical control data of spontaneous tumors in transgenic CByB6F1-Tg(HRAS)2Jic (Tg.rasH2) mice. | Int. J. Toxicol. 32(1):48-57 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2013) | Incidence of spontaneous non-neoplastic lesions in transgenic CBYB6F1-Tg(HRAS)2Jic mice. | Toxicol Pathol 41(8):1137-45 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2014) | The 26-week Tg.rasH2 mice carcinogenicity studies: microscopic examination of only select tissues in low- and mid-dose groups. | Toxicol Pathol 42(7):1153-7 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2014) | Relationship of body weight parameters with the incidence of common spontaneous tumors in Tg.rasH2 mice. | Toxicol Pathol 42(7):1143-52 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2014) | Trend analysis of body weight parameters, mortality, and incidence of spontaneous tumors in Tg.rasH2 mice. | Int. J. Toxicol. 33(6):475-81 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2015) | Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose (MTD) in Future Studies. | Toxicol Pathol 43(5):611-20 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2016) | Regulatory Forum Opinion Piece*: Retrospective Evaluation of Doses in the 26-week Tg.rasH2 Mice Carcinogenicity Studies: Recommendation to Eliminate High Doses at Maximum Tolerated Dose in Future Studies. A Response to the Counterpoints. | Toxicol Pathol 44(1):5-8 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2016) | Renal Tumors in 26-Week Tg.Rash2 Mice Carcinogenicity Studies. | Toxicol Pathol 44(5):633-5 | |||
| Paranjpe MG, et al. Mouse over for full list |
(2016) | Progression of Serosal Vascular Proliferative Lesions to Hemangiosarcomas in the Uterus of the 26-Week Tg.rasH2 Mice Carcinogenicity Studies. | Int. J. Toxicol. | ADMET, Tox & Safety Assessment | ||
| Pritchard JB, et al. Mouse over for full list |
(2003) | The role of transgenic mouse models in carcinogen identification. | Environ. Health Perspect. 111(4):444-54 | |||
| Yamamoto S, et al. Mouse over for full list |
(1998) | Validation of transgenic mice harboring the human prototype c-Ha-ras gene as a bioassay model for rapid carcinogenicity testing. | Toxicol. Lett. 102-103:473-8 | |||
| Yamamoto S, et al. Mouse over for full list |
(1996) | Rapid induction of more malignant tumors by various genotoxic carcinogens in transgenic mice harboring a human prototype c-Ha-ras gene than in control non-transgenic mice. | Carcinogenesis 17(11):2455-61 | |||
| Usui T, et al. Mouse over for full list |
(2001) | CB6F1-rasH2 mouse: overview of available data. | Toxicol Pathol 29 Suppl:90-108 | |||
| Urano K, et al. Mouse over for full list |
(2006) | Use of IC tags in short-term carcinogenicity study on CB6F1 TGrasH2 mice. | J Toxicol Sci 31(5):407-18 | |||
| Takegawa K, et al. Mouse over for full list |
(2000) | A mechanistic study of ovarian carcinogenesis induced by nitrofurazone using rasH2 mice. | Toxicol Pathol 28(5):649-55 | |||
| Suemizu H, et al. Mouse over for full list |
(2002) | Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing. | Mol. Carcinog. 34(1):1-9 | |||
| Ohnishi Y, et al. Mouse over for full list |
(2001) | Induction of drug metabolism-related enzymes by methylcholanthrene and phenobarbital in transgenic mice carrying human prototype c-Ha-ras gene and their wild type littermates. | Exp. Anim. 50(1):33-9 | |||
| Morton D, et al. Mouse over for full list |
(2002) | The Tg rasH2 mouse in cancer hazard identification. | Toxicol Pathol 30(1):139-46 | |||
| Mitsumori K, et al. Mouse over for full list |
(1998) | Pathological features of spontaneous and induced tumors in transgenic mice carrying a human prototype c-Ha-ras gene used for six-month carcinogenicity studies. | Toxicol Pathol 26(4):520-31 | |||
| Maronpot RR, et al. Mouse over for full list |
(2000) | Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model. | Toxicology 146(2-3):149-59 | |||
| Kanno H, et al. Mouse over for full list |
(2003) | Historical Background Data in CB6F1-Tg-rasH2 Mice and CB6F1-nonTg-rasH2 Mice over a 26-Week Experimental Period | J Toxicol Pathol. 16(4):267-274 | |||
| Gulezian D, et al. Mouse over for full list |
(2000) | Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment. | Toxicol Pathol 28(3):482-99 |
Welcome! Tell us a little about yourself